RENTON HOLLINGS sold $249K of ANAB

RENTON HOLLINGS sold 5,000 shares of ANAPTYSBIO, INC (ANAB) at $49.87 ($0.25M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RENTON HOLLINGS
Published Oct 2, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANAB
Neutral
medium confidence
Mentioned
$ANAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANABNeutralLow
01

Why it matters

The disclosed sale is modest in size relative to ANAB's market cap, so price impact is expected to be limited.

02

Market read

A routine insider sale with modest dollar value; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases that may offset the negative perception of the insider sale.

Relevance 3/10Novelty 3/10Timing: after‑hours filing today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ANABNeutralMedium confidence
Context

Director Renton Hollings sold 5,000 shares of ANAB for $249,371, reducing his stake to 10,995 shares under a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $250k sale by a director is modest but could be interpreted as a negative signal, especially given the open‑market nature of the transaction.

Market effects

Minimal impact on the biotech sector; insider sales are routine.

No broader regional effect.

Limited to ANAB shareholders.

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Renton Hollings

    Director of Anaptysbio, Inc.

  • Anaptysbio, Inc.

    Biotech firm developing therapies for rare diseases.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.